RA'ANANA, Israel, Feb. 22,
2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira
Technologies"), a breakthrough medical technology company targeting
to supersede mechanical ventilators, has unveiled an exclusive
in-house capability designed to simulate both the arterial and
venous blood parameters of patients with specific medical
conditions without the need of in vivo animal testing. This
platform has played, and will continue to play, a vital role in
advancing the development of our HYLA Blood Sensor and VORTX
Orbiting blood oxygenation delivery system, which are the core
technologies of the Inspira ART500.
Using unique methods and equipment, our team of scientists has
the ability to simulate human blood conditions based on a
predefined medical profile. The proprietary setting allows the
management of blood parameters continuously and in real-time for a
range of blood flow rates in order to simulate a patient's
oxygen-deficient and carbon dioxide-rich blood after it has flowed
through body organs and tissues.
We believe that these break-through capabilities may enable us
to further expand our research within a shorter timeframe and with
a better use of resources, thereby reducing time and costs. The
increased access to data is an important contributing factor
towards efforts to accelerate the development, testing and release
of new technologies and products as well as for more advanced
verification and validation prior to regulatory submissions. This
platform allows Inspira Technologies to control the blood
parameters over a wide range, allowing it to test the efficacy and
accuracy of its technologies in key scenarios, such as simulating
the blood parameters of patients who may suffer from acute medical
conditions. The Company's high-end lab capabilities include the
means for monitoring oxygen and carbon dioxide levels and detecting
hemolysis and other key parameters and elements under extreme
conditions.
The Chief Technology Officer of Inspira Technologies, Dr.
Daniella Yeheskely-Hayon, stated: "Inspira Technologies focuses
on developing advanced blood monitoring and oxygen delivery
technologies through its high-end testing platforms which allows it
perform wider range-controlled testing while minimizing the need to
perform in vivo animal testing."
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology (INSPIRA
ART), designed to rebalance patient oxygen saturation levels. This
technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. The Company's products have not yet been
tested or used in humans and has not been approved by any
regulatory entity.
For more information, please visit our corporate website:
https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the potential benefits
of its high-end platform, that the platform will continue to play a
vital role in advancing the development of the Inspira ART500, and
the belief that these break-through capabilities may enable the
Company to expand its research in a cost-efficient manner. These
forward-looking statements and their implications are based solely
on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2022
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website, www.sec.gov
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-introduces-high-end-platform-for-bio-mimicking-blood-parameters-for-development-and-testing-of-core-technologies-302068715.html
SOURCE Inspira Technologies